SEQUANA overview

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent ......

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent ......

Sequana Medical is a Belgian commercial-stage medical device company that uses its proprietary alfapump and Direct Sodium Removal (DSR) technologies to ......

PRESS RELEASE 19 MARCH 2020 07:00 CET REGULATED INFORMATION Continued strong progress in U.S. NASH-related and global heart failure programmes Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast presentation today at 14:00 CET / 09:00 ET Ghent, BELGIUM – 19 March 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart...

Ghent, BELGIUM – 12 March 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) , an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the full year ended 31 December 2019 and outlook for 2020 on Thursday 19 March 2020. The management team will host a conference call with a live webcast presentation at 14.00 CET / 09:00 ET on the day of the results. The webcast can be accessed by registering via the investors...

REGULATED INFORMATION Ghent, BELGIUM – 21 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "...

REGULATED INFORMATION Ghent, BELGIUM – 3 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the " Belgian...

PRESS RELEASE REGULATED INFORMATION 29 January 2020, 07:00 CET Ghent, Belgium, 29 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding...